Here's what we'll cover
Here's what we'll cover
Why So Many Employer Plans Still Say No to GLP-1s for Weight Loss
If you get health insurance through work and your prescription for Wegovy or Zepbound was denied, you are in the majority. Even as GLP-1 medications have become some of the most prescribed drugs in the country, most employers still do not cover them for weight loss.
The reasons are less about medicine and more about money, uncertainty, and how long patients stay on treatment. Understanding the employer side of the decision can help you figure out your next move.
How Many Employers Actually Cover GLP-1s for Weight Loss?
The best data comes from the 2025 KFF Employer Health Benefits Survey, along with focus groups KFF held with more than 100 companies, summarized in a Peterson KFF Health System Tracker brief.
| Employer size | Share covering GLP-1s for weight loss in largest plan, 2025 |
|---|---|
| 200 or more workers | 19% |
| 5,000 or more workers | 43% (up from 28% in 2024) |
Coverage is much more common for type 2 diabetes. Drugs like Ozempic and Mounjaro are typically on the formulary for diabetes, which is why a weight loss prescription can be denied even when the same molecule would be approved for blood sugar control.
The Five Main Reasons Employers Skip Coverage
1. The Bill Is Bigger Than Expected
Among the largest firms that covered GLP-1s for weight loss, 59% said use was higher than expected and 66% said the drugs had a significant effect on prescription spending, according to the KFF analysis. Focus group participants described annual pharmacy spending jumps of 30% to more than 100%, and one said GLP-1s went from 32nd to first on its list of drug costs.
2. Treatment Rarely Ends
Employers worried that people were not getting off the drugs. Clinical evidence supports that concern: in the STEP 1 extension study, participants regained about two thirds of their lost weight within a year of stopping semaglutide. For a benefits manager, that means a potentially lifelong expense rather than a short course of treatment.
3. The Savings Show Up Later, Often for Someone Else
GLP-1s can reduce serious cardiovascular events. In the SELECT trial, semaglutide lowered major adverse cardiovascular events by 20% in adults with overweight or obesity and established heart disease. But many of those savings appear years later, and the average worker changes jobs well before then. Employers pay today while a future employer or Medicare may capture the benefit.
4. Concerns About Misuse and Shifting Diagnoses
Some employers in the KFF focus groups said they saw enrollees obtaining diabetes diagnoses to qualify for coverage. Others pointed to rebates that "got dramatically worse," which raised their net cost even when list prices held steady.
5. Smaller Firms Cannot Absorb the Risk
A small or mid sized employer with a self funded plan can see its costs swing sharply if just a handful of employees start long term therapy. KFF estimates that 34% of non elderly adults with employer coverage, about 36.2 million people, have a BMI that would medically qualify them for a GLP-1. That pool is simply too large for many plans to cover without guardrails.
How Employers That Do Cover GLP-1s Manage It
Companies that keep coverage tend to add conditions rather than offer open access. Common approaches include:
- Requiring a meeting with a dietitian, case manager, or therapist, or enrollment in a lifestyle program. KFF found 34% of covering firms did this in 2025, up from 10% in 2024.
- Prior authorization tied to BMI thresholds, sometimes BMI 35 or higher
- Step therapy that requires trying lower cost options first
- Limiting coverage to people with diabetes or specific comorbidities
- Separate GLP-1 vendor programs that bundle coaching with prescriptions
What Has Changed for Patients
The cost picture outside insurance is very different than it was even two years ago. Manufacturers now sell several weight loss products directly to patients at lower cash prices, including the oral options approved in the past year. Eli Lilly's Foundayo (orforglipron), approved by the FDA on April 1, 2026, launched at $149 per month for the lowest dose through LillyDirect, and the Wegovy pill launched at a similar starting price, according to Fierce Pharma. Injectable Wegovy and Zepbound are also available at reduced self pay prices through manufacturer programs.
That shift matters because some employers now reason that if a patient can buy the drug for a few hundred dollars a month, the plan does not need to cover it. For patients, it means an employer denial is no longer the end of the road.
What You Can Do If Your Employer Will Not Cover It
- Read your plan's formulary and exclusion list so you know whether the drug is excluded entirely or just requires prior authorization.
- Ask your doctor whether you have a covered indication, such as type 2 diabetes, established cardiovascular disease, obstructive sleep apnea, or MASH, that could support a different coverage pathway.
- If you are denied, request the reason in writing and ask your prescriber to submit an appeal with a letter of medical necessity.
- Compare manufacturer cash prices and current GLP-1 coupons and savings programs.
- Raise it with HR during open enrollment. Employer decisions respond to employee demand, especially when paired with data on absenteeism and chronic disease costs.
Questions to Ask Your HR Team or Plan
- Does our plan exclude weight loss medications entirely, or does it require prior authorization?
- Are there lifestyle program or coaching requirements for GLP-1 coverage?
- Is coverage different for diabetes, heart disease, or sleep apnea indications?
- Is the employer considering adding coverage in the next plan year?
- Do we have an employee assistance or wellness program that offsets medication costs?
No waiting list. No insurance needed.
Frequently Asked Questions
What percentage of employers cover GLP-1s for weight loss?
In the 2025 KFF Employer Health Benefits Survey, 19% of firms with 200 or more workers covered GLP-1s for weight loss in their largest plan. Among firms with 5,000 or more workers, coverage rose to 43%, up from 28% in 2024.
Why do employers refuse to cover Wegovy or Zepbound?
Employers cite high and rising costs, higher than expected use, the fact that most patients stay on treatment long term, savings that appear years later, and concerns about misuse. Many smaller self funded plans also cannot absorb the financial risk.
Why is Ozempic covered but Wegovy is not?
Many employer plans cover GLP-1s for type 2 diabetes but exclude drugs used for weight loss. Ozempic is approved for diabetes, while Wegovy is approved for weight management, so the same active ingredient can be treated differently depending on the indication.
What requirements do employers add when they cover GLP-1s?
Common guardrails include prior authorization with BMI thresholds, step therapy, limiting coverage to certain conditions, and requiring participation in a lifestyle or coaching program. KFF found 34% of covering firms required such a program in 2025.
Can I appeal if my employer plan denies a GLP-1?
Yes. Ask for the denial reason in writing, then have your prescriber submit an appeal with a letter of medical necessity documenting your BMI, related conditions, and prior treatments. If the drug is a plan exclusion rather than a coverage decision, an appeal is less likely to succeed.
How can I afford GLP-1s without employer coverage?
Manufacturer direct programs now offer lower cash prices, including oral options like Foundayo and the Wegovy pill starting around $149 per month for the lowest dose. Compare self pay prices, savings programs, and telehealth options with your doctor.
The Bottom Line
Employers are not ignoring the evidence on GLP-1 medications. Most are weighing large, open ended costs against benefits that may arrive after an employee has moved on. That is why only 19% of firms with 200 or more workers covered these drugs for weight loss in 2025, while nearly half of the very largest employers did, usually with strict guardrails.
If your plan says no, look at other covered indications, appeal with good documentation, and compare today's much lower cash prices. To find a prescriber who can help with prior authorization or self pay options, compare vetted telehealth providers. Always talk with your doctor before starting or changing a GLP-1 medication.